Monday, October 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 8, 2025

MongoDB and Bath & Body Works have been highlighted as Zacks Bull and Bear of the Day

View original at finance.yahoo.com
MongoDB and Bath & Body Works have been highlighted as Zacks Bull and Bear of the Day For Immediate Release Chicago, IL – December 8, 2025 – Zacks Equity Research shares MongoDB MDB as the Bull of the Day and Bath & Body Works, Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Performance would have been worse had it not been for an extended fall sale

    80% confidence

  • Bath & Body Works' core demand engine is weakening, signaling erosion in brand relevance and consumer engagement

    80% confidence

  • MongoDB has surpassed Zacks Consensus Analyst Estimates by 69.30% over the past four quarters

    80% confidence

  • Q4 sales were down in the high single digits

    80% confidence

  • MDB shares are a buy

    80% confidence

  • North American consumers are spending less on non-essential home products

    80% confidence

  • Company expects EPS growth of ~30% and revenue growth of 20%

    80% confidence

  • Zacks Consensus Analyst Estimates suggest negative earnings growth over the next two years for Bath & Body Works

    80% confidence

  • Top stock-picking strategies have blown away the S&P's +7.7% average gain per year with average gains of +48.4%, +50.2% and +56.7% per year since 2000

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
MongoDB and Bath & Body Works have been highlighted as Zacks Bull and Bear of the Day — Source | Via News | ViaNews Market